Compounded tirzepatide dose conversion claims: what's real

What's this video probably claiming?

Based on the caption and hashtags, @dr.diegosantriia is walking viewers through how to convert doses of compounded tirzepatide, likely explaining how to calculate the correct volume when drawing from a vial based on concentration. The hashtags "tg" and "lipoless" are strongly associated with Brazilian compounding pharmacy networks and off-label tirzepatide sourcing communities. With 2.8 million views, this video is almost certainly reaching people who are self-administering compounded tirzepatide without a prescribing physician. The creator is likely framing this as harm reduction, arguing that dosing errors are dangerous and that knowing the math protects users. That framing sounds reasonable on the surface. The problem is that dose conversion guidance distributed via social media, regardless of the presenter's credentials, is not a substitute for individualized medical oversight, and compounded tirzepatide formulations vary in concentration across pharmacies, making any single "formula" potentially dangerous when applied broadly.

What does the science actually show?

Tirzepatide is a dual GIP and GLP-1 receptor agonist studied in the SURMOUNT clinical program. SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed that 15 mg weekly produced mean weight loss of 20.9% over 72 weeks in adults with obesity. The approved titration schedule starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg increments every four weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg. These intervals exist because the drug has a half-life of approximately five days, and slower titration reduces nausea, vomiting, and the risk of more serious gastrointestinal adverse events. The FDA-approved product, Zepbound and Mounjaro, uses a fixed-concentration auto-injector that removes the need for volume calculation entirely. Compounded versions use powder reconstituted with bacteriostatic water, meaning the final concentration depends entirely on how much diluent is added, and that number is not standardized across compounders. Dose conversion errors in this context are not hypothetical; they are arithmetically inevitable when users receive inconsistent guidance.

Where does the social media noise diverge from clinical reality?

The most dangerous assumption embedded in content like this is that dose conversion is a learnable skill that can be safely distributed as general advice. It cannot. A video that says "for a 10 mg/mL vial, draw 0.25 mL for 2.5 mg" is only correct for that specific concentration. Compounded vials in circulation range from 5 mg/mL to 20 mg/mL or higher depending on the pharmacy, and Brazilian telehealth and compounding markets have even less standardization than U.S. ones. A viewer who applies the "correct" formula to the wrong vial could administer two to four times the intended dose. Severe tirzepatide overdose presents as protracted vomiting, hypoglycemia in certain populations, and pancreatitis risk, and there is no antidote. Beyond the math, social media content normalizes self-titration, which removes the clinical check that exists to catch people who are escalating too fast or experiencing early warning signs of adverse effects. The hashtag ecosystem around "lipoless" and similar brands specifically targets people operating outside the medical system.

What should you actually know?

Compounded tirzepatide is not FDA-approved. The FDA placed tirzepatide on its drug shortage list, which temporarily permitted compounding under 503A and 503B provisions, but enforcement status has shifted and continues to change. The FDA released a statement in early 2025 clarifying that tirzepatide shortage determinations were being reassessed, which has direct legal implications for compounders. More practically: compounded peptide formulations do not undergo the same sterility, potency, and stability testing as approved drugs. A 2023 analysis of compounded semaglutide vials found significant potency variability across samples. There is no equivalent published data yet for compounded tirzepatide, but there is no pharmacological reason to expect better quality control. If you are using or considering tirzepatide for weight management, a regulated telehealth provider can prescribe FDA-approved formulations, supervise titration, and actually adjust your dose based on your response, which is what a TikTok video structurally cannot do.